ArticleRespiratory research2026
Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStudies suggest that the complement pathway may play a role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). We evaluated associations between complement pathway gene expression and clinical outcomes in patients with IPF.
methodsRNA was extracted from blood samples collected at enrollment into the IPF-PRO Registry. Patients were divided into discovery (n = 261) and validation (n = 609) cohorts. Patients were followed prospectively while receiving usual care. Using Cox proportional hazards models, we evaluated associations between expression of 45 complement pathway genes and three clinical outcomes. Analyses were unadjusted and adjusted for clinical variables at enrollment.
resultsEight complement pathway genes (CR1, CD59, C2, C1QTNF6, ITGB3, C1QBP, CD55, CR2) were associated with ≥ 1 outcome in the discovery cohort and evaluated in the validation cohort. In the discovery cohort, in unadjusted analyses, higher expression of the membrane-bound complement regulators CR1, CD55, and CD59 was associated with increased risk (hazard ratios [HRs]: 1.75 [95% CI 1.27, 2.41], 1.40 [1.06, 1.85] and 1.62 [1.17, 2.23], respectively), and higher expression of complement pathway component C2 with a decreased risk (HR 0.75 [0.61, 0.91]), of disease progression (absolute decline in forced vital capacity % predicted ≥ 10%, death, or lung transplant). Associations of CR1, CD55 and C2 with disease progression persisted in the validation cohort in adjusted analyses. In the discovery cohort, in unadjusted analyses, higher expression of CR1 and CD55 was associated with increased risk (HRs 2.66 [1.68, 4.23] and 1.90 [1.24, 2.93], respectively), and higher expression of C2 with a decreased risk (HR 0.61 [0.46, 0.80]), of respiratory death; associations with CR1, CD55, and C2 persisted in the validation cohort in adjusted analyses. In the validation cohort, increased expression of C2 was associated with reduced risk of respiratory hospitalization in adjusted analyses (HR 0.65 [0.50, 0.83]). Principal component analysis identified a composite score including complement components and regulators that was associated with increased risk of disease progression and respiratory death in both cohorts.
conclusionsHigher expression of complement regulators and lower expression of complement components, individually and in combination, may be biomarkers of progression of IPF.
trial registrationClinicalTrials.gov (NCT01915511). Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.